Core Insights - Dyadic International, Inc. is focusing on the production and monetization of alternative proteins, which is expected to provide significant near-term revenue opportunities as partners prepare for multiple product launches in this sector [2] - The company has received renewed interest in leveraging its C1 platform for human and animal health vaccines and diagnostics, highlighted by a 3 million grant from the Bill & Melinda Gates Foundation [2] - Dyadic will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13 to 16, 2025, to engage with global partners [1][9] Alternative Proteins Business - The company is advancing its Human Serum Albumin product, expected to launch in the first half of 2025, and anticipates achieving a productivity milestone worth 500,000 during the same period [6] - Dyadic is in discussions for its recombinant transferrin products, which offer a consistent, animal-free alternative to serum-derived transferrin [6] - A recombinant dairy enzyme for cheese production is in the final stages of launch preparation, with additional dairy enzymes under development [6] Diagnostic and Vaccine Development - Collaborations with ViroVax are focused on developing a self-assembling ferritin nanoparticle H5-2.3.4.4b A/Astrakhan bird flu antigen for diagnostic testing and vaccine applications [7][14] - The C1-produced ferritin nanoparticle Mpox vaccine is also in early development stages [7] - Initial studies using the C1-produced H5 antigen have shown promising results in generating neutralizing antibodies in poultry and cattle sera, indicating potential for diagnostics and disease prevention [14] Company Overview - Dyadic International, Inc. specializes in the large-scale manufacture of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications [10][12] - The company utilizes the C1-cell protein production platform, which is based on the fungus Thermothelomyces heterothallica, to enhance the development and reduce production costs of biologic vaccines and drugs [11]
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference